Cannabix Technologies Provides Update on Marijuana Breathalyzer Development
For immediate release. Vancouver, British Columbia, March 29, 2016: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) is pleased to provide an update on its technology development and recent presentation at the PITTCON 2016 conference in Atlanta, Georgia. PITTCON is one of the world’s largest annual premier conference and expositions on laboratory science. Cannabix and University of Florida researchers (UF) were invited to present the state of the art technology at sessions focused on drugged driving and illicit drug detection. Dr. Jared Boock gave a talk titled “Detection of Tetrahydrocannabinol (THC) and Related Compounds in Human Breath Using High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)”. The presentation outlined how Cannabix and University of Florida researchers have made significant headway toward the development of an innovative FAIMS-based instrument for the detection of THC in human breath. PITTCON also provided Cannabix with the opportunity to cultivate strategic alliances with groups interested in advancing the implementation of breath-based drug detection for law enforcement.
Cannabix management and University of Florida chemists have confirmed the ability to specifically detect THC at standard temperature and pressure using our unique FAIMS cell coupled with mass spectrometry (FAIMS-MS). We have successfully isolated THC and THC-related by-products in controlled simulated breath samples, with the current FAIMS-MS configuration demonstrating THC detection limits which are at least 10 times more sensitive than previously reported in the exhaled breath literature. The Company also reports that it has been evaluating the feasibility of detecting other volatile compounds of interest using FAIMS-MS with promising preliminary results for cocaine models in simulated breath samples.
Development of the Cannabix instrument is rapidly advancing. Many proprietary components, such as a high-voltage generator, non-radioactive ionization source, and array detector are being integrated with the novel FAIMS cell to provide the most technologically advanced FAIMS-based instrument in the world.
Dr. Raj Attariwala, Cannabix’s Chief Scientific Officer, states, “Development of a standalone FAIMS based device for trace detection of THC in breath is progressing well. With the expertise of the Yost lab at UF, we have demonstrated the unique ability to have a device which allows real time analysis of exhaled breath without any cumbersome extraction techniques. Our recent analysis of the presentations at PITTCON affirms our belief that Cannabix is developing one of the most advanced and sensitive real time THC specific breath detection devices for roadside use by law enforcement.”
Kal Malhi, President of Cannabix stated, “Our recent visit to the University of Florida and the presentations at PITTCON reaffirm our belief that Cannabix is developing the best technology in the field of detection of THC in exhaled breath. Our FAIMS-MS device is now recognized as a very accurate and highly sensitive device and we are moving quickly moving towards miniaturization of the bench top device. Agreements are in place with parts suppliers and parts required to build the portable device are now on order and we expect to have a portable FAIMS-MS device for field testing in the coming months.”
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. This technology would be used to provide detection of use of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. In particular, Cannabix is focused on developing breath testing devices for THC detection that would target recent use of THC, in contrast to saliva or urine testing for THC which can be invasive and take considerable time for laboratory analysis. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact us at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financing; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact
For additional information on Cannabix Technologies Inc. please visit our website at http://www.cannabixtechnologies.com or email info@cannabixtechnologies.com
For immediate release. Vancouver, British Columbia, March 29, 2016: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) is pleased to provide an update on its technology development and recent presentation at the PITTCON 2016 conference in Atlanta, Georgia. PITTCON is one of the world’s largest annual premier conference and expositions on laboratory science. Cannabix and University of Florida researchers (UF) were invited to present the state of the art technology at sessions focused on drugged driving and illicit drug detection. Dr. Jared Boock gave a talk titled “Detection of Tetrahydrocannabinol (THC) and Related Compounds in Human Breath Using High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)”. The presentation outlined how Cannabix and University of Florida researchers have made significant headway toward the development of an innovative FAIMS-based instrument for the detection of THC in human breath. PITTCON also provided Cannabix with the opportunity to cultivate strategic alliances with groups interested in advancing the implementation of breath-based drug detection for law enforcement.
Cannabix management and University of Florida chemists have confirmed the ability to specifically detect THC at standard temperature and pressure using our unique FAIMS cell coupled with mass spectrometry (FAIMS-MS). We have successfully isolated THC and THC-related by-products in controlled simulated breath samples, with the current FAIMS-MS configuration demonstrating THC detection limits which are at least 10 times more sensitive than previously reported in the exhaled breath literature. The Company also reports that it has been evaluating the feasibility of detecting other volatile compounds of interest using FAIMS-MS with promising preliminary results for cocaine models in simulated breath samples.
Development of the Cannabix instrument is rapidly advancing. Many proprietary components, such as a high-voltage generator, non-radioactive ionization source, and array detector are being integrated with the novel FAIMS cell to provide the most technologically advanced FAIMS-based instrument in the world.
Dr. Raj Attariwala, Cannabix’s Chief Scientific Officer, states, “Development of a standalone FAIMS based device for trace detection of THC in breath is progressing well. With the expertise of the Yost lab at UF, we have demonstrated the unique ability to have a device which allows real time analysis of exhaled breath without any cumbersome extraction techniques. Our recent analysis of the presentations at PITTCON affirms our belief that Cannabix is developing one of the most advanced and sensitive real time THC specific breath detection devices for roadside use by law enforcement.”
Kal Malhi, President of Cannabix stated, “Our recent visit to the University of Florida and the presentations at PITTCON reaffirm our belief that Cannabix is developing the best technology in the field of detection of THC in exhaled breath. Our FAIMS-MS device is now recognized as a very accurate and highly sensitive device and we are moving quickly moving towards miniaturization of the bench top device. Agreements are in place with parts suppliers and parts required to build the portable device are now on order and we expect to have a portable FAIMS-MS device for field testing in the coming months.”
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. This technology would be used to provide detection of use of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. In particular, Cannabix is focused on developing breath testing devices for THC detection that would target recent use of THC, in contrast to saliva or urine testing for THC which can be invasive and take considerable time for laboratory analysis. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact us at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financing; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact
For additional information on Cannabix Technologies Inc. please visit our website at http://www.cannabixtechnologies.com or email info@cannabixtechnologies.com
